Intellia Therapeutics, Inc.
NTLA
$12.33
$0.131.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -34.62% | 67.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -34.62% | 67.01% | |||
| Cost of Revenue | 9.66% | -6.74% | |||
| Gross Profit | -29.80% | 22.34% | |||
| SG&A Expenses | -27.56% | 3.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.05% | -2.82% | |||
| Operating Income | -1.85% | 11.45% | |||
| Income Before Tax | -0.46% | 5.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.46% | 5.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.46% | 5.47% | |||
| EBIT | -1.85% | 11.45% | |||
| EBITDA | -2.08% | 11.67% | |||
| EPS Basic | 1.72% | 10.15% | |||
| Normalized Basic EPS | -1.11% | 16.31% | |||
| EPS Diluted | 1.72% | 10.15% | |||
| Normalized Diluted EPS | -1.11% | 16.31% | |||
| Average Basic Shares Outstanding | 2.22% | 5.20% | |||
| Average Diluted Shares Outstanding | 2.22% | 5.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||